From bench to market: translational medicine in the development of molecular imaging agents
Lin Zhu1,2,4,Hank F.Kung2,3*,4
1.Key Laboratory of Radiopharmaceuticals (Beijing Normal University),Ministry of Education,Beijing 100875,China 2.Departments of Radiology,University of Pennsylvania,Philadelphia,PA 19014,USA 3.Departments of Pharmacology,University of Pennsylvania,Philadelphia, PA 19014,USA 4.Beijing Institute for Brain Disorders,Capital Medical University,Beijing 100069,China
From bench to market: translational medicine in the development of molecular imaging agents
摘要:In the past two decades translational medicine,which encompasses efforts to move discoveries from the laboratory to clinical applications,has received significant attention.We will discuss the recent development of two brain imaging agents for studying neurodegenerative diseases as examples of from bench to clinic.The agents,TRODAT-1 and AV-45 (Amyvid),have faced diverse hurdles along the pathway from laboratory to FDA registration and widespread clinical adoption.
出版日期: 2015-04-22
引用本文:
Lin Zhu,Hank F.Kung. From bench to market: translational medicine in the development of molecular imaging agents[J]. 转化医学研究, 2014, 4(1): 26-31.
